Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Sunday, 08 August 2021 11:17

James Stevenson

Written by
Sunday, 08 August 2021 11:17

Balazs Halmos

Written by
Sunday, 08 August 2021 11:17

Antoinette Wozniak

Written by
Sunday, 08 August 2021 11:17

Haiying Cheng

Written by
Sunday, 08 August 2021 11:17

Khaled Hassan

Written by
Sunday, 08 August 2021 11:17

Thomas Braun

Written by
Sunday, 08 August 2021 11:17

Misako Nagasaka

Written by
Sunday, 08 August 2021 11:17

Karen Dziubek

Written by
Sunday, 08 August 2021 11:17

Shirish M. Gadgeel

Written by
I am the Chief of Division of Hematology/Oncology at Henry Ford Cancer Institute/Henry Ford Health System. I am a medical oncologist by training and my area of interest is lung cancer research in general and drug development in lung cancer, in particular. I have conducted and participated in many lung cancer specific trials and in phase I trials, including investigator initiated trials based on laboratory research. I have also been a principal investigator of a Southwest Oncology Group trial, S0528, S1507 and NCI protocol 7389. I was a co-author on major phase III trials ALEX and Keynote 189 which changed the standard of care. I have also engaged in many epidemiologic studies in the field of lung cancer, publishing on features of lung cancer in African Americans and in young patients. I have served as one of the PIs of multi-PI R21 to identify ‘driver’ genetic alterations in African-American lung cancer patients. I served as the co-leader of the Molecular Therapeutics Program of the Core Cancer Center Grant of Karmanos Cancer Institute before joining University of Michigan. I was also the site PI for the NO1 grant awarded to the California Cancer Consortium. Subsequently, I was co-leader of the Thoracic Oncology Research Program and the Mary Lou Kennedy Research Professor in Thoracic Oncology at the University of Michigan, where I worked before joining Henry Ford Cancer Institute. My clinical research experience spans 20 years. I am also a member of the steering Committee of the Lung Cancer Committee of Southwest Oncology Group (SWOG). I am a member of the Editorial Board of Clinical Lung Cancer and a reviewer for many journals including New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology and Journal of Thoracic Oncology. I have also served as faculty for the annual meeting of the American Society of Clinical Oncology (ASCO) and as a member of the Education Committee of ASCO. I am a member of the Communications Committee of the International Association of Study of Lung Cancer (IASLC). I was awarded by the NCI the Cancer Clinical Investigator Team Leadership Award in 2012.
Sunday, 08 August 2021 11:17

Jordi Bruna

Written by
Page 319 of 371